Shire is a global innovator in specialty biopharmaceuticals. Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Today, Shire is a renowned company focused on serving people with rare diseases and other highly specialized conditions. Shire Hellas was founded in 2009 with a mindful vision to deliver healthcare in therapeutic areas such as behavioral diseases and gastrointestinal disorders, and with the ultimate goal making the world a better place.
Contact
Shire Hellas S.A.
38 Vas. Constantinou Ave.
Athens 116 35
Greece
Tel: +30 216 900 4010
Web: shire.gr
To read the interview with Christos Dakas, MD of Shire Greece and Cyprus, click here
A strong proponent of the value of orphan drugs, Shire Greece’s Managing Director, Christos Dakas, shares his insights on the recent merger with Baxalta, the necessity of exempting orphan and…
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said Christophe Weber, Takeda’s CEO, after the USD 62 billion…
Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a state-of-art stem cell therapy. She highlights the…
Kieran Leahy, general manager of Takeda in the Czech Republic and Slovakia, recounts how he has led the transformation of Takeda into a specialty care organization at the local level,…
Originally from Croatia, Vatroslav Mateljic was appointed as the general manager of Takeda Sweden in April 2019. Mateljic outlines how Takeda is integrating Shire operations in Sweden, highlights how Sweden’s…
Peter Streibl, general manager of Takeda Thailand, highlights the importance of emerging markets for Takeda globally, as well as the 50–year long commitment of Takeda to Thailand and Thai patients.…
Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda…
The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The stem cell itself having been discovered in Canada, Marc LePage,…
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
Carla Benedito, general manager of Shire Portugal, provides useful insight into the rare diseases landscape in Portugal. Carla discusses market access models for innovative and rare treatments, encouraging dialogue between…
With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald…
Eric Tse, general manager of Shire Canada, highlights the affiliate’s exciting journey over the past four years, including new office location in downtown Toronto, and the launch of six new…
Dr. Wolfgang Schnitzel, general manager of Shire Austria, and Karl-Heinz Hofbauer, site lead Vienna and managing director for the Technical Operations business, discuss the huge impact of Shire’s 32 billion…
See our Cookie Privacy Policy Here
